TriSalus Life Sciences, Inc. (TLSI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 5M 10M 15M Q3 '22: 3.9M Q4 '22: 3.2M Q1 '23: 3M Q2 '23: 4.6M Q3 '23: 5.2M Q4 '23: 5.7M Q1 '24: 6.5M Q2 '24: 7.4M Q3 '24: 7.3M Q4 '24: 8.3M Q1 '25: 9.2M Q2 '25: 11.2M Q3 '25: 11.6M Q4 '25: 13.2M Q1 '26: 8.9M Q2 '26: 11.4M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit Quarterly

0 4M 8M 12M Q3 '22: 3.2M Q4 '22: 2.4M Q1 '23: 2.3M Q2 '23: 3.8M Q3 '23: 4.6M Q4 '23: 5.1M Q1 '24: 5.5M Q2 '24: 6.5M Q3 '24: 6.3M Q4 '24: 7M Q1 '25: 7.7M Q2 '25: 9.4M Q3 '25: 9.7M Q4 '25: 11.4M Q1 '26: 7.7M Q2 '26: 9.9M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '21: -807.3K Q4 '21: -1.1M Q1 '22: -669.8K Q2 '22: -288.3K Q3 '22: -8.1M Q4 '22: -11.8M Q1 '23: -10.1M Q2 '23: -11.4M Q3 '23: -18.6M Q4 '23: -14.2M Q1 '24: -11.7M Q2 '24: -8.2M Q3 '24: -8.7M Q4 '24: -7.6M Q1 '25: -7.3M Q2 '25: -7.3M Q3 '25: -9M Q4 '25: -3.3M Q1 '26: -8.4M Q2 '26: -9.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: 1.9M Q4 '21: 2.9M Q1 '22: -7.9M Q2 '22: -8.7M Q3 '22: -8.1M Q4 '22: -22.5M Q1 '23: -8.3M Q2 '23: -14M Q3 '23: -1.4M Q4 '23: -35.6M Q1 '24: -13.2M Q2 '24: -4.3M Q3 '24: -2.4M Q4 '24: -10.1M Q1 '25: -10.4M Q2 '25: -8.3M Q3 '25: -10.8M Q4 '25: -9.8M Q1 '26: 1.5M Q2 '26: -9.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 700K 1.4M 2.1M Q3 '22: 701K Q4 '22: 816K Q1 '23: 662K Q2 '23: 772K Q3 '23: 589K Q4 '23: 582K Q1 '24: 971K Q2 '24: 912K Q3 '24: 1M Q4 '24: 1.2M Q1 '25: 1.5M Q2 '25: 1.8M Q3 '25: 1.9M Q4 '25: 1.8M Q1 '26: 1.2M Q2 '26: 1.5M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '21: -365.1K Q4 '21: -680.9K Q1 '22: -426K Q2 '22: -696.7K Q3 '22: -22.9M Q4 '22: -8.3M Q1 '23: -10.5M Q2 '23: -9.2M Q3 '23: -21.7M Q4 '23: -9.2M Q1 '24: -10.9M Q2 '24: -13.4M Q3 '24: -10.8M Q4 '24: -5.7M Q1 '25: -4.5M Q2 '25: -7.3M Q3 '25: -3.7M Q4 '25: -2.5M Q1 '26: -6.5M Q2 '26: -10.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q4 '22: -8.5M Q1 '23: -10.5M Q2 '23: -9.3M Q3 '23: -21.8M Q4 '23: -9.5M Q1 '24: -10.9M Q2 '24: -13.5M Q3 '24: -11M Q4 '24: -5.8M Q1 '25: -5.3M Q2 '25: -7.4M Q3 '25: -3.9M Q4 '25: -2.5M Q1 '26: -6.6M Q2 '26: -10.2M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q3 '22: 311.8K Q1 '23: 16.2M Q2 '23: 446.3K Q3 '23: 13.2M Q1 '24: 23.3M Q2 '24: 23.9M Q3 '24: 26.5M Q1 '25: 28.5M Q2 '25: 32.9M Q3 '25: 43.1M Q1 '26: 52.3M Q2 '26: 58.3M Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-150.00 -100.00 -50.00 0.00 50.00 100.00 150.00 Q2 '23: -141.74 Q3 '23: -115.93 Q4 '24: -1.33 Q1 '25: -1.12 Q2 '25: -1.18 Q2 '23 Q3 '23 Q4 '24 Q1 '25 Q2 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.